Home / Hormonal Therapies

Hormonal Therapies

Novo Nordisk Presents Positive Phase 2 Data for Somapacitan in Childhood Growth Hormone Deficiency

Athens, Greece, 28 September 2018 ­– Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.1 There are currently no approved once-weekly treatments for growth hormone deficiency. The REAL …

Read More »

Ferring and Celmatix Partner to Advance Care in Reproductive Medicine and Accelerate Development of Personalized Interventions

SAINT-PREX, Switzerland & NEW YORK–(BUSINESS WIRE)–Ferring Pharmaceuticals and Celmatix today announced an ambitious genomics collaboration aimed at uncovering new insights into ovarian biology and accelerating the development of personalized interventions in reproductive medicine and women’s health. This collaboration will leverage both Ferring and Celmatix’s significant expertise in women’s reproductive health …

Read More »

FDA Approves New Indications for Ferring’s Human Growth Hormone Zomacton

PARSIPPANY, N.J.–(BUSINESS WIRE)–Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for injection in four additional pediatric indications: Idiopathic short stature (ISS) Short stature associated with Turner syndrome Short stature born small for gestational age (SGA) with no catch-up growth by 2 …

Read More »

Versartis’ Growth Hormone Drug Fails to Meet Primary Endpoint of Non-Inferiority in Phase 3 Study

MENLO PARK, Calif., Sept. 21, 2017 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that the VELOCITY Phase 3 clinical trial of somavaratan in pediatric growth hormone …

Read More »

FDA Approves Triptodur for Treatment of Patients 2 Years and Older with Central Precocious Puberty

ATLANTA and LAUSANNE, Switzerland, June 30, 2017 /PRNewswire/ — Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, and Debiopharm International SA, part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Triptodur™ for the treatment of pediatric patients 2 …

Read More »

Hormonal Contraceptives Linked to an Increased Risk of Rare Brain Cancer

Long-term use of contraceptive pills may double the risk of developing brain cancer, according to a new study. Scientists say that taking hormonal contraception, particularly progesterone-only methods, for five years more than doubles the chance of developing glioma, a rare type of brain cancer which affects roughly five in 100,000 …

Read More »